• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

白蛋白可能预防肝硬化和顽固性腹水患者腹腔穿刺术诱发的循环功能障碍的发病:一项初步研究。

Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study.

作者信息

Tan Hiang Keat, James Paul Damien, Wong Florence

机构信息

Division of Gastroenterology, Department of Medicine, Toronto General Hospital, 9EN/222, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada.

Department of Gastroenterology and Hepatology, Singapore General Hospital, Outram Road, Singapore, 169608, Singapore.

出版信息

Dig Dis Sci. 2016 Oct;61(10):3084-3092. doi: 10.1007/s10620-016-4140-3. Epub 2016 Apr 5.

DOI:10.1007/s10620-016-4140-3
PMID:27048451
Abstract

BACKGROUND

Large-volume total paracentesis may result in paracentesis-induced circulatory dysfunction, which is associated with poor outcomes.

AIMS

To explore the short- and long-term effects of paracentesis-induced circulatory dysfunction on systemic hemodynamics, renal function and other cirrhosis-related complications in patients with refractory ascites, following subtotal large-volume paracentesis.

METHODS

Patients with cirrhosis and refractory ascites without renal dysfunction had systemic hemodynamics, renal function, and neurohormones (plasma active renin, aldosterone, norepinephrine and angiotensin II) measured pre- and 6 days post-paracentesis. Paracentesis was limited to ≤8 L with 6-8 g of albumin per liter ascites drained. Patients were followed up until transjugular intrahepatic portosystemic shunt insertion, liver transplantation, or death. Paracentesis-induced circulatory dysfunction was defined as >50 % increase in plasma active renin 6 days post-paracentesis.

RESULTS

Fifty-seven patients (mean age 59.0 ± 9.4 years) had mean 6.8 ± 1.8 L of ascites removed with 9 ± 3 g of albumin given/L of ascites drained. Patients were followed up for 715 ± 104 days. Twenty-three patients (40.4 %) developed paracentesis-induced circulatory dysfunction with unchanged serum creatinine on day six, despite worsening of hemodynamics (mean arterial pressure 90 ± 10 mmHg at baseline vs. 84 ± 8 mmHg on day six, p < 0.05). Similar hemodynamic changes were observed among patients without paracentesis-induced circulatory dysfunction. There was no significant difference in the long-term renal function or cirrhosis-related complications between the groups.

CONCLUSION

The occurrence of paracentesis-induced circulatory dysfunction, as defined by plasma active renin, may not have a significant short- and long-term impact on renal function or cirrhosis-related complications in patients with refractory ascites who undergo subtotal paracentesis with albumin infusion.

摘要

背景

大量腹腔穿刺放液可能导致穿刺诱导的循环功能障碍,这与不良预后相关。

目的

探讨在大量腹腔穿刺放液术后,穿刺诱导的循环功能障碍对顽固性腹水患者全身血流动力学、肾功能及其他肝硬化相关并发症的短期和长期影响。

方法

对无肾功能不全的肝硬化顽固性腹水患者,在腹腔穿刺放液术前及术后6天测量其全身血流动力学、肾功能及神经激素(血浆活性肾素、醛固酮、去甲肾上腺素和血管紧张素II)。腹腔穿刺放液量限制在≤8L,每排出1L腹水补充6 - 8g白蛋白。对患者进行随访,直至行经颈静脉肝内门体分流术、肝移植或死亡。穿刺诱导的循环功能障碍定义为腹腔穿刺放液术后6天血浆活性肾素升高>50%。

结果

57例患者(平均年龄59.0±9.4岁)平均排出腹水6.8±1.8L,每排出1L腹水给予9±3g白蛋白。患者随访715±104天。23例患者(40.4%)出现穿刺诱导的循环功能障碍,尽管血流动力学恶化(基线时平均动脉压为90±10mmHg,术后第6天为84±8mmHg,p<0.05),但术后第6天血清肌酐未改变。在未发生穿刺诱导的循环功能障碍的患者中也观察到类似的血流动力学变化。两组患者的长期肾功能或肝硬化相关并发症无显著差异。

结论

以血浆活性肾素定义的穿刺诱导的循环功能障碍的发生,可能对接受补充白蛋白的部分腹腔穿刺放液术的顽固性腹水患者的肾功能或肝硬化相关并发症没有显著的短期和长期影响。

相似文献

1
Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study.白蛋白可能预防肝硬化和顽固性腹水患者腹腔穿刺术诱发的循环功能障碍的发病:一项初步研究。
Dig Dis Sci. 2016 Oct;61(10):3084-3092. doi: 10.1007/s10620-016-4140-3. Epub 2016 Apr 5.
2
Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study.米多君与白蛋白预防肝硬化患者腹水穿刺诱导性循环功能障碍的比较:一项随机初步研究。
J Clin Gastroenterol. 2014 Feb;48(2):184-8. doi: 10.1097/MCG.0b013e31829ae376.
3
Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.预防腹腔穿刺术引起的循环功能障碍:米多君与白蛋白对比。一项随机试点研究。
Liver Int. 2008 Aug;28(7):1019-25. doi: 10.1111/j.1478-3231.2008.01734.x. Epub 2008 Apr 11.
4
Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.特利加压素与白蛋白治疗肝硬化腹腔穿刺术诱发循环功能障碍的随机对照研究
J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 2):303-7. doi: 10.1111/j.1440-1746.2006.04182.x.
5
Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study.预防肝硬化腹水穿刺引起的循环功能障碍:标准剂量与半剂量白蛋白。一项前瞻性、随机、非盲的初步研究。
Dig Liver Dis. 2011 Nov;43(11):881-6. doi: 10.1016/j.dld.2011.06.001. Epub 2011 Jul 8.
6
Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study.去甲肾上腺素和白蛋白在肝硬化穿刺放腹水诱发循环功能障碍中的作用:一项随机试点研究
J Intern Med. 2006 Jul;260(1):62-8. doi: 10.1111/j.1365-2796.2006.01654.x.
7
Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study.特利加压素与白蛋白对肝硬化并张力性腹水患者经穿刺放腹水治疗后动脉血容量影响的比较:一项随机试点研究。
Gut. 2002 Jan;50(1):90-4. doi: 10.1136/gut.50.1.90.
8
Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites.肝硬化伴利尿剂抵抗性腹水患者对单次大量腹腔穿刺放液的心血管、肾脏及神经体液反应
Am J Gastroenterol. 1997 Mar;92(3):394-9.
9
[Albumin infusion for paracentesis in patients with cirrhosis: dogma or evidence?].[肝硬化患者腹腔穿刺术白蛋白输注:教条还是证据?]
Rev Med Suisse. 2012 Oct 17;8(358):1956, 1958-60.
10
Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial.右旋糖酐40与白蛋白联合大量腹腔穿刺术治疗肝硬化张力性腹水:一项随机对照试验
Ann Hepatol. 2002 Jan-Mar;1(1):29-35.

引用本文的文献

1
Advances in the diagnosis and management of clinically significant portal hypertension in cirrhosis: A narrative review.肝硬化中具有临床意义的门静脉高压症的诊断与管理进展:一篇叙述性综述。
World J Hepatol. 2025 Jun 27;17(6):104761. doi: 10.4254/wjh.v17.i6.104761.
2
Drainage of ascites in cirrhosis.肝硬化腹水的引流
World J Hepatol. 2024 Sep 27;16(9):1245-1257. doi: 10.4254/wjh.v16.i9.1245.
3
Management of refractory ascites.难治性腹水的处理。

本文引用的文献

1
Safety, complications and outcome of large volume paracentesis with or without albumin therapy in children with severe ascites due to liver disease.大体积腹腔穿刺术联合或不联合白蛋白治疗肝病致严重腹水患儿的安全性、并发症和结局。
J Hepatol. 2015 Nov;63(5):1126-32. doi: 10.1016/j.jhep.2015.06.019. Epub 2015 Jun 29.
2
Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.肝硬化患者急性肾损伤的诊断与管理:国际腹水俱乐部修订的共识建议
J Hepatol. 2015 Apr;62(4):968-74. doi: 10.1016/j.jhep.2014.12.029. Epub 2015 Jan 28.
3
Clin Mol Hepatol. 2023 Jan;29(1):16-32. doi: 10.3350/cmh.2022.0104. Epub 2022 Jun 9.
4
Clinical implications of prompt ascitic drain removal in cirrhosis with refractory ascites.肝硬化难治性腹水及时腹腔引流的临床意义。
Singapore Med J. 2021 Dec;62(12):659-664. doi: 10.11622/smedj.2021049. Epub 2021 Apr 19.
5
HEP-Net opinion on the management of ascites and its complications in the setting of decompensated cirrhosis in the resource constrained environment of Pakistan.HEP-Net关于在巴基斯坦资源有限环境下失代偿期肝硬化患者腹水及其并发症管理的意见。
Pak J Med Sci. 2020 Jul-Aug;36(5):1117-1132. doi: 10.12669/pjms.36.5.2407.
6
Nutrition in Chronic Liver Disease.慢性肝病中的营养
Curr Treat Options Gastroenterol. 2019 Dec;17(4):602-618. doi: 10.1007/s11938-019-00252-3.
7
Establishing an indwelling peritoneal catheter as a standard procedure for hospitalized patients with ascites: Retrospective data on feasibility, effectiveness and safety.建立留置腹腔导管作为住院腹水患者的标准程序:可行性、有效性和安全性的回顾性数据。
United European Gastroenterol J. 2019 Jun;7(5):673-681. doi: 10.1177/2050640619842442. Epub 2019 Apr 3.
8
Paracentesis-induced acute kidney injury in decompensated cirrhosis - prevalence and predictors.失代偿期肝硬化患者腹腔穿刺术诱发的急性肾损伤——患病率及预测因素
Clin Exp Hepatol. 2019 Mar;5(1):55-59. doi: 10.5114/ceh.2019.83157. Epub 2019 Feb 20.
9
Prevention of the Paracentesis-Induced Circulatory Dysfunction (PICD) in Cirrhosis: Is the SPA Treatment Worthwhile?肝硬化患者腹腔穿刺术诱发循环功能障碍(PICD)的预防:SPA治疗是否值得?
Dig Dis Sci. 2016 Oct;61(10):2773-2775. doi: 10.1007/s10620-016-4248-5. Epub 2016 Aug 23.
Renal failure in cirrhosis: prerenal azotemia, hepatorenal syndrome and acute tubular necrosis.
肝硬化中的肾衰竭:肾前性氮质血症、肝肾综合征和急性肾小管坏死。
Nephrol Dial Transplant. 2012 Jul;27(7):2625-8. doi: 10.1093/ndt/gfs067. Epub 2012 Apr 6.
4
Diastolic dysfunction in asymptomatic type 2 diabetes mellitus with normal systolic function.收缩功能正常的无症状2型糖尿病患者的舒张功能障碍
J Cardiovasc Dis Res. 2011 Oct;2(4):213-22. doi: 10.4103/0975-3583.89805.
5
Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials.大量腹腔穿刺术患者输注白蛋白:随机试验的荟萃分析。
Hepatology. 2012 Apr;55(4):1172-81. doi: 10.1002/hep.24786.
6
Management of ascites in cirrhosis.肝硬化腹水的管理。
J Gastroenterol Hepatol. 2012 Jan;27(1):11-20. doi: 10.1111/j.1440-1746.2011.06925.x.
7
Active renin mass concentration to determine aldosterone-to-renin ratio in screening for primary aldosteronism.活性肾素质量浓度用于在原发性醛固酮增多症筛查中确定醛固酮与肾素比值。
Int J Nephrol Renovasc Dis. 2011;4:115-20. doi: 10.2147/IJNRD.S22245. Epub 2011 Jul 28.
8
Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study.β受体阻滞剂可引起肝硬化伴难治性腹水患者经皮穿刺放液后循环功能障碍:一项交叉研究。
J Hepatol. 2011 Oct;55(4):794-9. doi: 10.1016/j.jhep.2011.01.034. Epub 2011 Feb 24.
9
Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites.大量肝腹水患者大量腹腔穿刺放液所致循环功能障碍的预测因素
J Cardiovasc Dis Res. 2010 Jul;1(3):136-44. doi: 10.4103/0975-3583.70914.
10
Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis.细菌 DNA 易位与肝硬化患者全身循环异常和肝内内皮功能障碍有关。
Hepatology. 2010 Dec;52(6):2044-52. doi: 10.1002/hep.23918. Epub 2010 Oct 26.